Table of Contents
ISRN Oncology
Volume 2014, Article ID 605691, 7 pages
http://dx.doi.org/10.1155/2014/605691
Review Article

Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant

1Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
2Department of Anaesthesia and Intensive Care Unit, Indraprastha Apollo Hospital, New Delhi 110076, India

Received 23 February 2014; Accepted 18 March 2014; Published 30 March 2014

Academic Editors: R. A. Abrams and H. Al-Ali

Copyright © 2014 Nida Iqbal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Fermé, N. Mounier, M. Diviné et al., “Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Études des Lymphomes de l'Adulte H89 Trial,” Journal of Clinical Oncology, vol. 20, no. 2, pp. 467–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Diehl, P. M. Mauch, and N. L. Harris, “Hodgkin’s disease,” in Cancer: Principles and Practice of Oncology, V. T. Devita Jr., S. Hellman, and S. A. Rosenberg, Eds., vol. 2, pp. 2339–2387, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001. View at Google Scholar
  3. N. Schmitz, B. Pfistner, M. Sextro et al., “Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2065–2071, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Horning, M. Fanale, S. deVos et al., “Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort,” Annals of Oncology, vol. 20, article 118, 2008. View at Google Scholar
  5. A. Josting, C. Rudolph, M. Mapara et al., “Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG),” Annals of Oncology, vol. 16, no. 1, pp. 116–123, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Sirohi, D. Cunningham, R. Powles et al., “Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma,” Annals of Oncology, vol. 19, no. 7, pp. 1312–1319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Filmont, C. Gisselbrecht, X. Cuenca et al., “The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation,” Cancer, vol. 110, no. 6, pp. 1361–1369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Moskowitz, J. Yahalom, T. Kewalramani et al., “Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma,” Blood, vol. 116, no. 23, pp. 4934–4937, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Crump, “Management of Hodgkin lymphoma in relapse after autologous stem cell transplant,” Hematology, vol. 2008, no. 1, pp. 326–333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Derenzini, D. Buglio, and A. Younes, “Novel therapy of relapsed and refractory classical Hodgkin’s lymphoma,” European Oncology & Haematology, vol. 7, no. 3, pp. 203–210, 2011. View at Google Scholar
  11. A. Josting, L. Nogová, J. Franklin et al., “Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1522–1529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Smith, K. van Besien, J. Carreras et al., “Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant,” Biology of Blood and Marrow Transplantation, vol. 14, no. 8, pp. 904–912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. O. Freytes, F. R. Loberiza, J. D. Rizzo et al., “Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry,” Blood, vol. 104, no. 12, pp. 3797–3803, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Anderlini, R. Saliba, S. Acholonu et al., “Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience,” Haematologica, vol. 93, no. 2, pp. 257–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Robinson, A. Sureda, C. Canals et al., “Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome,” Haematologica, vol. 94, no. 2, pp. 230–238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Sarina, L. Castagna, L. Farina et al., “Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability,” Blood, vol. 115, no. 18, pp. 3671–3677, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. K. S. Peggs, A. Sureda, W. Qian et al., “Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes,” British Journal of Haematology, vol. 139, no. 1, pp. 70–80, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Younes, A. K. Gopal, S. E. Smith et al., “Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183–2189, 2012. View at Publisher · View at Google Scholar
  19. R. Chen, J. M. Palmer, S. H. Thomas et al., “Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma,” Blood, vol. 119, no. 26, pp. 6379–6381, 2012. View at Publisher · View at Google Scholar
  20. A. K. Gopal, R. Ramchandren, O. A. O'Connor et al., “Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation,” Blood, vol. 120, no. 3, pp. 560–568, 2012. View at Publisher · View at Google Scholar
  21. R. J. Jones, C. D. Gocke, Y. L. Kasamon et al., “Circulating clonotypic B cells in classic Hodgkin lymphoma,” Blood, vol. 113, no. 23, pp. 5920–5926, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Younes, J. Romaguera, F. Hagemeister et al., “A pilot study of rituximab in patients with recurrent, classic Hodgkin disease,” Cancer, vol. 98, no. 2, pp. 310–314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Oki, B. Pro, L. E. Fayad et al., “Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma,” Cancer, vol. 112, no. 4, pp. 831–836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. O'Mahony, J. E. Janik, J. A. Carrasquillo et al., “Yttrium-90 radiolabeled humanized monoclonal antibody to CD25 in refractory and relapsed Hodgkin’s lymphoma,” Blood, vol. 112, article 231, 2008. View at Google Scholar
  25. R. Little, R. E. Wittes, D. L. Longo, and W. H. Wilson, “Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 584–588, 1998. View at Google Scholar · View at Scopus
  26. L. Devizzi, A. Santoro, V. Bonfante et al., “Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease,” Annals of Oncology, vol. 5, no. 9, pp. 817–820, 1994. View at Google Scholar · View at Scopus
  27. H. Venkatesh, N. Di Bella, T. P. Flynn, M. J. Vellek, K. A. Boehm, and L. Asmar, “Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma,” Clinical Lymphoma, vol. 5, no. 2, pp. 110–115, 2004. View at Google Scholar · View at Scopus
  28. A. Spencer, K. Reed, and C. Arthur, “Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim,” Internal Medicine Journal, vol. 37, no. 11, pp. 760–766, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. N. L. Bartlett, D. Niedzwiecki, J. L. Johnson et al., “Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804,” Annals of Oncology, vol. 18, no. 6, pp. 1071–1079, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. de Filippi, D. Aldinucci, D. Galati et al., “Effects of bendamustine on apoptosis and colony-initiating precursors in Hodgkin lymphoma cells,” Journal of Clinical Oncology, vol. 29, supplement, abstract e18559, 2011. View at Google Scholar
  31. A. J. Moskowitz, P. A. Hamlin, M. A. Perales et al., “Phase II study of bendamustine in relapsed and refractory Hodgkin,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 456–460, 2013. View at Google Scholar
  32. F. Pajonk, K. Pajonk, and W. H. McBride, “Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition,” International Journal of Radiation Oncology Biology Physics, vol. 47, no. 4, pp. 1025–1032, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. K. A. Blum, J. L. Johnson, D. Niedzwiecki, G. P. Canellos, B. D. Cheson, and N. L. Bartlett, “Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206,” Leukemia & Lymphoma, vol. 48, no. 7, pp. 1313–1319, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Mendle, J. Kelly, S. Voci et al., “Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma,” Annals of Oncology, vol. 19, no. 10, pp. 1759–1764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. Kirschbaum, B. H. Goldman, J. M. Zain et al., “A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517,” Leukemia and Lymphoma, vol. 53, no. 2, pp. 259–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Younes, A. Sureda, D. Ben-Yehuda et al., “Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a Phase II Study,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2197–2203, 2012. View at Publisher · View at Google Scholar
  37. N. T. Ihle and G. Powis, “Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. P. B. Johnston, D. J. Inwards, J. P. Colgan et al., “A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma,” American Journal of Hematology, vol. 85, no. 5, pp. 320–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. T. A. Fehniger, S. Larson, K. Trinkaus et al., “A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma,” Blood, vol. 118, no. 19, pp. 5119–5125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. V. Georgakis, Y. Li, G. Z. Rassidakis, H. Martinez-Valdez, L. J. Medeiros, and A. Younes, “Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death,” Clinical Cancer Research, vol. 12, no. 2, pp. 584–590, 2006. View at Google Scholar · View at Scopus
  41. N. Schoof, F. von Bonin, L. Trumper, and D. Kube, “HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells,” Cell Communication and Signaling, vol. 7, article 17, 2009. View at Publisher · View at Google Scholar
  42. K. G. Lucas, D. Salzman, A. Garcia, and Q. Sun, “Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)- specific cytotoxic T-lymphocytes for recurrent EBV-positive Hodgkin disease,” Cancer, vol. 100, no. 9, pp. 1892–1901, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Sebti, “Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy,” Cancer Cell, vol. 7, no. 4, pp. 297–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. T. E. Witzig, H. Tang, I. N. M. Micallef et al., “Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas,” Blood, vol. 118, no. 18, pp. 4882–4889, 2011. View at Publisher · View at Google Scholar · View at Scopus